Akebia Therapeutics (AKBA) Sees Large Volume Increase
Akebia Therapeutics Inc (NASDAQ:AKBA) shares saw an uptick in trading volume on Tuesday . 9,257,745 shares traded hands during trading, an increase of 785% from the previous session’s volume of 1,045,966 shares.The stock last traded at $8.10 and had previously closed at $7.34.
Several research firms recently weighed in on AKBA. Zacks Investment Research cut Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 1st. BidaskClub raised Akebia Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 7th. Finally, ValuEngine cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 22nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Akebia Therapeutics presently has an average rating of “Hold” and a consensus price target of $15.04.
The firm has a market cap of $462.18 million, a price-to-earnings ratio of -4.50 and a beta of 1.46.
ILLEGAL ACTIVITY WARNING: This story was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://theolympiareport.com/2019/03/15/akebia-therapeutics-akba-sees-large-volume-increase.html.
Akebia Therapeutics Company Profile (NASDAQ:AKBA)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Recommended Story: Cost of Capital Explained
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.